MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

PURPOSE: To determine if BRAF and/or MEK inhibitor-induced GPNMB expression renders melanomas sensitive to CDX-011, an antibody-drug conjugate targeting GPNMB. EXPERIMENTAL DESIGN: The TCGA melanoma dataset was interrogated for a panel of MITF-regulated melanosomal differentiation antigens, includin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168941/
https://ncbi.nlm.nih.gov/pubmed/27515299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1192
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires